ECVT · Ecovyst Inc.

This acquisition represents a strategic expansion of Ecovyst’s specialty chemical platform, specifically targeting the on-purpose SO₂ and derivative businesses—including sodium metabisulphite (SMBS), sodium bisulphite (SBS), and sodium thiosulphate (STS)—as explicitly defined in the Share Purchase Agreement’s ‘Business’ definition. The $190 million all-cash transaction, structured as a cross-border share purchase involving US and Canadian entities, signals a deliberate move to consolidate capabilities in sulfur-based chemistry, a segment aligned with Ecovyst’s existing catalyst and purification technologies. The use of English law and ICC arbitration reflects the international nature of the deal and the parties’ preference for neutral, enforceable dispute resolution. Notably, the Purchasers are bearing the cost of warranty and indemnity (W&I) insurance—a common feature in private M&A that mitigates execution risk related to seller representations while limiting direct recourse against the Sellers beyond narrow indemnities. Closing remains conditional on customary items including absence of a Material Adverse Change, regulatory approvals, and other standard pre-closing undertakings detailed in Schedule 2 of the agreement. Given the size relative to Ecovyst’s market capitalization and the strategic fit with its core industrial chemical focus, this transaction carries high materiality for investors assessing growth trajectory, integration capacity, and capital allocation discipline. Forward-looking statements in the filing caution that timing and completion are not assured, underscoring execution risk ahead of anticipated Q2 2026 close.